KRAS INHIBITORS

The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer. La présente...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GUO, Deqi, LIU, Tao, BARBERIS, Mario, PRIETO VALLEJO, Maria Lourdes, JOHNSTON, Richard Duane, BASTIAN, Jolie Anne, LAMAR, Jason Eric, FURNESS, Kelly Wayne, RUBIO, Almudena, ZIA-EBRAHIMI, Mohammad Sadegh, ROJO, Isabel, ZHAO, Gaiying, BARDA, David Anthony, MOLERO FLOREZ, Victoriano, GARCIA LOSADA, Pablo, SI, Chong, BAUMGARTNER, Matthew Patrick, CARBALLARES MARTIN, Santiago, HENRY, James Robert, RODRIGUEZ, Michael John, LUMERAS AMADOR, Wenceslao, GUTIERREZ SANFELICIANO, Sonia Maria
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer. La présente invention concerne des composés de formule : dans laquelle A, B, D1, X, Y, Z, G, R1, R2, et R3a sont tels que décrits dans la description, des sels pharmaceutiquement acceptables de ceux-ci, et des méthodes d'utilisation de ces composés et des sels pharmaceutiquement acceptables de ceux-ci pour traiter des patients atteints d'un cancer.